C L I N I C A L S T U D Y S U M M A R Y

151557_GreenLightSummary_B 5/31/07 4:29 PM Page 10G R E E N L I G H TC L I N I C A L S T U D Y S U M M A R YStudy & PublicationKey FindingsLaser: 80WHigh Power (80 W) potassiumtitanyl-phosphatelaservaporization of the prostatein 66 high risk patientsJournal:J Urol 2005Authors:O. ReichA. BachmannM. SiebelsA. HofstetterC.G. StiefT. SulserNumber of PatientsProstate Volume: Mean(range)Procedure Time: MeanNo Catheterization:Length of Catheterization (LOC):(range)Catheter Removed MorningAfter Surgery:Re-catheterization:Catheter Irrigations Required:Number of Patients6649 ± 30 mL(15 – 150)49 ± 19 min6% (4 patients)1.8 ± 1.4 days(0 – 7 days)64% (42 patients)11% (7 patients)23% (14/62 patients)12 month results(n = 51)Etiology:All patients withASA score ≥ 3Oral coumarin derivatives:16 patientsThrombocyte aggregationinhibitors: 10 patientsSevere bleeding disorder:3 patientsIPSS Score: % ImprovementMean (score range)Qmax: % ImprovementMean (range)PVR: % ImprovementMean (range)Anesthesia68%6.5 ± 4 (1 – 12)222%21.6 ± 7 (15 – 34)83%25 ± 31 (0 – 70)47% (31 patients) received spinal53% (35 patients) received generalHIGH RISK41% (27 patients) inurinary retentionAll patients stayedon medicationsFollow up:Mean 11.8 mos.ComplicationsMild Dysuria: Less Than 7 DaysRe-treatmentUTI-urinary Tract Infections withSignificant BacteriuriaBlood Transfusion% Observed9% (6 patients)3% (2 patients)*8% (5 patients)* Each patient (prostate volume 42 and 50 mL respectively) was in thefirst 10 men treated.0